Improve Analyte Preservation & Recovery with Advanced DBS Assays

Recovering analytes, including proteins, nucleic acids, bacteria or viruses from dried blood samples can be challenging, especially when existing dried blood microsampling technologies create reproducibility and reliability concerns. This webinar explores how engineered porous fiber technology can support a more reliable dry blood spot (DBS) approach, enabling consistent analyte recovery, ambient stabilization and simplified workflows that address limitations of conventional DBS methods.

A dry-state microsampling device is designed to collect, stabilize and transport biological samples in a test-ready format for downstream analysis. Combined with stabilizing chemistry, the fiber matrix supports consistent recovery of proteins, nucleic acids and immune cell-associated biomarkers from dried blood samples while reducing handling and cold-chain challenges associated with traditional workflows.

This webinar will present data from a multi-donor study comparing dry-state microsampling with conventional liquid blood collection. Using qPCR analysis of isolated mRNA, researchers observed comparable relative expression of biomarkers associated with T cells (CD3+, CD4+, CD8+), B cells and natural killer cells between dried and liquid samples, suggesting that the fiber matrix preserves representative immune cell population profiles for downstream immunogenomic analysis. The study also demonstrated quantitative recovery of genomic DNA proportional to sample input volume, along with minimal measurable loss of plasmid DNA to the fiber matrix.

The featured speakers will also share preliminary findings from an HIV therapeutic monitoring study using dry-state sampling, with early results suggesting analytical performance comparable to traditional wet collection while delivering the logistical advantages of dry-state sampling. Together, these studies demonstrate how engineered fiber materials can support reliable molecular analysis while substantially simplifying dried blood collection workflows.

Register for this webinar to learn how DBS workflows can improve analyte preservation, recovery and decentralized molecular testing

Speakers

Ben Cobb, PhD, Founder and CEO, ReadyGo™ Diagnostics

Ben has spent his entire career innovating new diagnostic products and has founded several public and private start-ups. Some of his products have now become embedded into routine clinical practice, including Genedrive® which was arguably the world’s first true point-of-care molecular platform and is providing a new standard of NHS care. As CEO, Ben is responsible for overseeing ReadyGo’s day-to-day operations, the delivery of its strategy and new product innovation.

Message Presenter

Ayokunle Olanrewaju, PhD, Assistant Professor, University of Washington

Dr. Ayokunle Olanrewaju is an Assistant Professor in the Departments of Mechanical Engineering and Bioengineering at the University of Washington, where his research focuses on developing innovative diagnostic and therapeutic monitoring technologies for point-of-care and decentralized healthcare applications. His work combines microfluidics, molecular assays and translational bioengineering to create rapid, user-friendly systems for disease monitoring and therapeutic drug analysis, particularly in HIV treatment and prevention.

Message Presenter

Ellen Weinzapfel, PhD, Global Marketing Manager, Porex

Ellen Weinzapfel, PhD, is the Global Marketing Manager at Porex, where she supports diagnostic and medtech customers developing advanced sample collection and biomolecule isolation solutions. She works closely with R&D, product development and commercial teams to translate material science capabilities into application-specific solutions for noninvasive sampling and decentralized diagnostics.

Message Presenter